RxDoctor Payments Data

Michael Lake, MD

Pulmonary Disease · Abington, PANPI 1548503907

Payments from drug & device makers

$735in general payments, 2019–2025

Across 27 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • GSK$159
  • Amgen$100
  • Olympus Corporation Of The Americas$53
  • Jazz Pharmaceuticals Inc.$48
  • Sanofi$43
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$735 in reported general payments places this provider in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$136,975
Medicare patients
487
Services billed
1,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter252$223,277
Spiriva RespimatTiotropium Bromide112$66,577
Breo ElliptaFluticasone/Vilanterol126$60,616
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr69$34,519
Incruse ElliptaUmeclidinium Bromide42$18,629
Fluticasone-SalmeterolFluticasone Propion/Salmeterol82$11,383
SymbicortBudesonide/Formoterol Fumarate27$10,118
Combivent RespimatIpratropium/Albuterol Sulfate11$8,557
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$7,862
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,457
Albuterol Sulfate HfaAlbuterol Sulfate146$5,940
Wixela InhubFluticasone Propion/Salmeterol41$4,914
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$4,385
Arnuity ElliptaFluticasone Furoate12$3,928
Tiotropium Bromide12$3,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$159$340,969501 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$20$82,996140 claims
AstraZenecaSymbicort, Breztri Aerosphere$250$17,57538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →